<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37167156</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>19</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.</ArticleTitle><Pagination><StartPage>517</StartPage><EndPage>522</EndPage><MedlinePgn>517-522</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7219a3</ELocationID><Abstract><AbstractText>Since the World Health Assembly established the Global Polio Eradication Initiative (GPEI) in 1988, two of the three wild poliovirus (WPV) serotypes (types 2 and 3) have been eradicated, and global WPV cases have decreased by more than 99.9%. Afghanistan and Pakistan remain the only countries where indigenous WPV type 1 (WPV1) transmission has not been interrupted. This report summarizes progress toward global polio eradication during January 1, 2021-March 31, 2023, and updates previous reports (1,2). In 2022, Afghanistan and Pakistan reported 22 WPV1 cases, compared with five in 2021; as of May 5, 2023, a single WPV1 case was reported in Pakistan in 2023. A WPV1 case was reported on the African continent for the first time since 2016, when officials in Malawi confirmed a WPV1 case in a child with paralysis onset in November 2021; neighboring Mozambique subsequently reported eight genetically linked cases. Outbreaks of polio caused by circulating vaccine-derived polioviruses (cVDPVs) can occur when oral poliovirus vaccine (OPV) strains circulate for a prolonged time in underimmunized populations, allowing reversion to neurovirulence (3). A total of 859 cVDPV cases occurred during 2022, an increase of 23% from 698 cases in 2021. cVDPVs were detected in areas where poliovirus transmission had long been eliminated (including in Canada, Israel, the United Kingdom, and the United States). In addition, cocirculation of multiple poliovirus types occurred in multiple countries globally (including Democratic Republic of the Congo [DRC], Israel, Malawi, Mozambique, Republic of the Congo, and Yemen). The 2022-2026 GPEI strategic plan targeted the goal of detecting the last cases of WPV1 and cVDPV in 2023 (4). The current global epidemiology of poliovirus transmission makes the likelihood of meeting this target date unlikely. The detections of poliovirus (WPV1 and cVDPVs) in areas where it had been previously eliminated underscore the threat of continued poliovirus spread to any area where there is insufficient vaccination to poliovirus (3). Mass vaccination and surveillance should be further enhanced in areas of transmission to interrupt poliovirus transmission and to end the global threat of paralytic polio in children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Scarlett E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Sharon A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Tallis</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>13</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37167156</ArticleId><ArticleId IdType="pmc">PMC10208367</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7219a3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication—worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep 2022;71:650–5. 10.15585/mmwr.mm7119a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Wilkinson AL, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF. Progress toward polio eradication—worldwide, January 2019–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1129–35. 10.15585/mmwr.mm7034a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7034a1</ArticleId><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Henderson E, Traoré MA, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2021–December 2022. MMWR Morb Mortal Wkly Rep 2023;72:366–71. 10.15585/mmwr.mm7214a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global polio eradication initiative; GPEI strategy 2022–2026. Geneva, Switzerland: World Health Organization; 2021. https://polioeradication.org/gpei-strategy-2022-2026</Citation></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, et al.; nOPV2 Working Group. Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine 2023;41(Suppl 1):A122–7. 10.1016/j.vaccine.2022.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Burns CC, Jorba J, et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing—worldwide, March–October 2021. MMWR Morb Mortal Wkly Rep 2022;71:786–90. 10.15585/mmwr.mm7124a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Immunization dashboard: global. Geneva, Switzerland: World Health Organization; 2022. https://immunizationdata.who.int/</Citation></Reference><Reference><Citation>Mohamed A, Akbar IE, Chaudhury S, et al. Progress toward poliomyelitis eradication—Afghanistan, January 2021–September 2022. MMWR Morb Mortal Wkly Rep 2022;71:1541–6. 10.15585/mmwr.mm7149a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7149a1</ArticleId><ArticleId IdType="pmc">PMC9762895</ArticleId><ArticleId IdType="pubmed">36480464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbaeyi C, Baig S, Safdar MR, et al. Progress toward poliomyelitis eradication—Pakistan, January 2021–July 2022. MMWR Morb Mortal Wkly Rep 2022;71:1313–8. 10.15585/mmwr.mm7142a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7142a1</ArticleId><ArticleId IdType="pmc">PMC9590290</ArticleId><ArticleId IdType="pubmed">36264783</ArticleId></ArticleIdList></Reference><Reference><Citation>Davlantes E, Greene SA, Tobolowsky FA, et al. Update on wild poliovirus type 1 outbreak—Southeastern Africa, 2021–2022. MMWR Morb Mortal Wkly Rep 2023;72:391–7. 10.15585/mmwr.mm7215a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7215a3</ArticleId><ArticleId IdType="pmc">PMC10121257</ArticleId><ArticleId IdType="pubmed">37053125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>